Medifast (MED) EBIAT (2016 - 2025)
Medifast (MED) has disclosed EBIAT for 16 consecutive years, with -$18.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 2364.88% year-over-year to -$18.1 million, compared with a TTM value of -$18.7 million through Dec 2025, down 992.97%, and an annual FY2025 reading of -$18.7 million, down 992.97% over the prior year.
- EBIAT was -$18.1 million for Q4 2025 at Medifast, down from -$2.3 million in the prior quarter.
- Across five years, EBIAT topped out at $47.0 million in Q2 2021 and bottomed at -$18.1 million in Q4 2025.
- Average EBIAT over 5 years is $19.5 million, with a median of $24.8 million recorded in 2022.
- Peak annual rise in EBIAT hit 130.41% in 2025, while the deepest fall reached 2364.88% in 2025.
- Year by year, EBIAT stood at $34.0 million in 2021, then dropped by 22.06% to $26.5 million in 2022, then tumbled by 77.24% to $6.0 million in 2023, then plummeted by 86.74% to $800000.0 in 2024, then plummeted by 2364.88% to -$18.1 million in 2025.
- Business Quant data shows EBIAT for MED at -$18.1 million in Q4 2025, -$2.3 million in Q3 2025, and $2.5 million in Q2 2025.